Popular Articles

Oncothyreon Announces Initiation Of Phase 3 Trial Of Stimuvax In Breast Cancer
Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Stimuvax is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon.
new payday loan lenders
Buy zoloft and forget about depression.
Smoking, High Blood Pressure And Diabetes In Mid-life Can Lead To Dementia
Middle aged people who smoke, have high blood pressure or diabetes are far more likely to develop dementia in later life, suggests research published ahead of print in the Journal of Neurology, Neurosurgery and Psychiatry.
News of the day
Ventana's Promising New Anti-Obesity Patent
Ventana Biotech Inc ("Ventana")(PINK SHEETS:VNTA), a biotechnology company that is developing a appetite-suppressing chewing gum, released detailed information about its innovative Anti-Obesity Chewing Gum.
Medical Devices

GE, Big Vendors Corner EMR Market; Smaller Vendors Explore Health 2.0

Staying ahead of the upcoming drive to sell electronic health records to hospitals and physicians may be difficult for smaller vendors, Pharmawire/Financial Times reports. General Electric announced a program last week to provide health care organizations with financing options to purchase health technology through its financial services arm even as it sells electronic records through its health care wing. Other large vendors like Cerner and McKesson will be able to keep up, but smaller producers will be left behind, industry experts said. A rush of new customers is expected in upcoming years because the American Recovery and Reinvestment Act provides incentives - more than $20 billion - for health providers to purchase the technology (Avallone and Longpre, 6/24). In other news, Atlas Venture, a venture capital firm, is gearing up to make investments that will "improve health care by empowering patients," the Wall Street Journal"s blog, Venture Capital Dispatch, reports. The company has recently invested in Keas, a health 2.0 company that develops Web technologies that help consumers "better their health." Atlas partner and technology specialist Jeff Fagnan said "the firm may make four or five of these types of investments with its current fund... which closed at $283 million last year" (Gormley, 6/25). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):